Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12656847 | 0.90 | ACACB (0.40) | ACACBKMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL1816354 | 0.89 | ACACB (0.43) | ACACBKMT2AACACA | |
| SCHEMBL502744 | 0.87 | ACACB (0.42) | ACACBKMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL1829568 | 0.84 | ACACB (0.53) | ACACBKMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL1811427 | 0.84 | ACACB (0.52) | ACACBKMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL1811705 | 0.83 | KMT2A (0.41) | ACACBKMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL1811424 | 0.83 | ACACB (0.47) | ACACBKMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL1827661 | 0.83 | KMT2A (0.41) | ACACBKMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL1812751 | 0.82 | ACACB (0.42) | ACACBKMT2AACACA | |
| SCHEMBL1810743 | 0.82 | ACACB (0.41) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910375-B1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | MERCK SHARP & DOHME (US) | 2011-05-11 | — | — | EP | claimed |
| US-7410976-B2 | Spirochromanone derivatives | MERCK & CO., INC. (US) | 2008-08-12 | — | — | US | claimed |
| WO-2007011811-A1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | MERCK & CO., INC. (US) | 2007-01-25 | — | — | WO | claimed |
| US-20070021453-A1 | Novel spirochromanone derivatives | MERCK SHARP & DOHME LLC | 2007-01-25 | — | — | US | claimed |
| EP-1910375-B1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | MERCK SHARP & DOHME (US) | 2011-05-11 | — | — | EP | disclosed |
| US-7935712-B2 | Spirochromanone derivatives as acetyl coenzyme A carboxylase (ACC) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935712-B2 | Spirochromanone derivatives as acetyl coenzyme A carboxylase (ACC) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935712-B2 | Spirochromanone derivatives as acetyl coenzyme A carboxylase (ACC) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090131464-A1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | MERCK SHARP & DOHME LLC | 2009-05-21 | — | — | US | disclosed |
| US-20090131464-A1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | MERCK SHARP & DOHME LLC | 2009-05-21 | — | — | US | disclosed |
| US-20090131464-A1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | MERCK SHARP & DOHME LLC | 2009-05-21 | — | — | US | disclosed |
| US-7410976-B2 | Spirochromanone derivatives | MERCK & CO., INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410976-B2 | Spirochromanone derivatives | MERCK & CO., INC. (US) | 2008-08-12 | — | — | US | disclosed |
| EP-1910375-A1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | Merck & Co., Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007011811-A1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | MERCK & CO., INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011809-A1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | MERCK & CO., INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021453-A1 | Novel spirochromanone derivatives | MERCK SHARP & DOHME LLC | 2007-01-25 | — | — | US | disclosed |
| WO-2007011811-A1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | MERCK & CO., INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021453-A1 | Novel spirochromanone derivatives | MERCK SHARP & DOHME LLC | 2007-01-25 | — | — | US | disclosed |
| US-20070021453-A1 | Novel spirochromanone derivatives | MERCK SHARP & DOHME LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021453-A1 | Novel spirochromanone derivatives | HSD17B7, CYP11B2, CYP11B1 | ACACB 37/4885KMT2A 3449/4885ALDH1A1 123/4885 |
| US-20090131464-A1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | ACACA, ACACB, ACAT1 | ACACB 2/4885KMT2A 2873/4885ALDH1A1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.